Kaken Pharmaceutical Co (TSE:4521) Net Income From Continuing Operations : 円2,966 Mil (TTM As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Kaken Pharmaceutical Co's net income from continuing operations for the three months ended in Dec. 2023 was 円2,607 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was 円2,966 Mil.

Kaken Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Kaken Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Net Income From Continuing Operations Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

24,922.00

26,592.00

18,657.00

13,885.00

6,817.00

Kaken Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															3,185.00	-3,709.00	2,511.00	1,557.00	2,607.00

Kaken Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,966 Mil.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines